Novartis spies new potential for Xolair with CSU filings
This article was originally published in Scrip
Executive Summary
Novartis is hoping to carve out another niche for its anti-IGE monoclonal antibody product for moderate to severe asthma, Xolair (omalizumab), this time in chronic spontaneous urticaria (CSU, also known as chronic idiopathic urticaria).